Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioLineRx Ltd. - American Depositary Shares (NQ:BLRX)

3.890 -0.050 (-1.27%)
Streaming Delayed Price Updated: 2:10 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioLineRx Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Earnings Scheduled For November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers NexImmune (NASDAQ:NEXI) shares rose 38.8% to $0.7 during Thursday's pre-market session. The market value of their outstanding shares is at $16.9 million. 
Via Benzinga
Recap: BioLine Rx Q2 Earnings
  BioLine Rx (NASDAQ:BLRX) reported its Q2 earnings results on Tuesday, August 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: BioLine Rx Q1 Earnings
BioLine Rx (NASDAQ:BLRX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: BioLine Rx Q4 Earnings
BioLine Rx (NASDAQ:BLRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 63 stocks hit new 52-week lows. 
Via Benzinga
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
US Markets Turn Higher As Dow Jumps Over 100 Points
U.S. stocks traded higher in volatile trading toward the end of trading, with the Dow Jones gaining more than 100 points on Monday. 
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX
From Rosen Law Firm
Via Business Wire
Dow, S&P 500 Drop In Volatile Trading Ahead Of Fed's Rate Decision
U.S. stocks traded lower in volatile trading toward the end of trading, with the Dow Jones dropping around 40 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
Why BioLineRx Shares Are Getting Obliterated Monday
BioLine RX Ltd - ADR (NASDAQ: BLRX) shares are trading lower by 32.21% to $1.06 Monday morning after the company announced a $15 million registered direct offering. What Else? 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
 
Via Benzinga
BioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate
BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous... 
Via Benzinga
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development... 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Performance Shipping Inc. (NASDAQ: PSHG) rose 41.7% to $ 0.94 in pre-market trading. Performance Shipping shares dipped around 64% on Friday after the company announced the pricing of an... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. 
Via Benzinga
Banned diamonds
Pres. Biden plans to rap the oil reserve to lower gasoline prices by a million barrels per day for 180 mn barrels. 
Via Talk Markets
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Earnings Scheduled For March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.